Sbir phase II: topic 338 - predictive biomarkers of adverse reactions to prostrate cancer radiotherapy
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201700033C
- Awardee
-
L2 Diagnostics LLC UEI GKA7VH5LFR25
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,996,011
Award facts
- Opportunity
-
- BAAN44CO7900149 Solicitation number
- Contract value 100% obligated
- $1,996,011.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- New Haven, CT 06511, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $1,996,011 |
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute (NIH NCI) awarded a Small Business Innovation Research (SBIR) Phase II contract to L2 Diagnostics LLC, a for-profit limited liability company, to develop predictive biomarkers for adverse reactions to prostate cancer radiotherapy. The $1,996,011.00 firm-fixed-price contract has a completion date of September 18, 2020 and is set aside for small businesses. L2 Diagnostics is a provider of goods and services to the federal government through grants, with a focus on biomedical research, diagnostics, therapeutics, and vaccines related to infectious diseases, cancer, and autoimmune disorders. The company has previously received funding from the National Institute of Allergy and Infectious Diseases, the National Cancer Institute, and the National Heart, Lung, and Blood Institute for research on Lyme disease, Zika virus, cancer immunotherapy, tick-borne diseases, tuberculosis, and malaria.
Quick answers
Who was awarded contract HHSN261201700033C?
HHSN261201700033C was awarded to L2 Diagnostics LLC by National Cancer Institute (National Institutes of Health) on September 19, 2017.
How much is contract HHSN261201700033C worth?
The government has obligated $1,996,011 on HHSN261201700033C.
Was contract HHSN261201700033C competed?
The extent of competition for HHSN261201700033C was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award